Vanguard Group
NRXP icon

Vanguard Group’s NRX Pharmaceuticals NRXP Stock Holding History

Vanguard Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.98M Buy
729,842
+194,886
+36% +$523K ﹤0.01% 3564
2025
Q3 		$1.77M Buy
534,956
+82,781
+18% +$237K ﹤0.01% 3614
2025
Q2 		$1.47M Buy
452,175
+63,250
+16% +$159K ﹤0.01% 3634
2025
Q1 		$797K Buy
388,925
+148,609
+62% +$419K ﹤0.01% 3779
2024
Q4 		$529K Hold
240,316
– – ﹤0.01% 3938
2024
Q3 		$406K Hold
240,316
– – ﹤0.01% 4023
2024
Q2 		$586K Buy
240,316
+96,311
+67% +$343K ﹤0.01% 3947
2024
Q1 		$680K Sell
144,005
-513
-0.4% -$2.36K ﹤0.01% 3935
2023
Q4 		$665K Sell
144,518
-541
-0.4% -$1.79K ﹤0.01% 3952
2023
Q3 		$377K Sell
145,059
-2,756
-2% -$9.17K ﹤0.01% 4134
2023
Q2 		$715K Hold
147,815
– – ﹤0.01% 4004
2023
Q1 		$974K Buy
147,815
+3,499
+2% +$35.5K ﹤0.01% 3927
2022
Q4 		$1.6M Buy
144,316
+289
+0.2% +$2.91K ﹤0.01% 3746
2022
Q3 		$1.06M Buy
144,027
+34,556
+32% +$233K ﹤0.01% 3978
2022
Q2 		$657K Buy
109,471
+1,939
+2% +$25.5K ﹤0.01% 4215
2022
Q1 		$2.63M Sell
107,532
-9,691
-8% -$315K ﹤0.01% 3843
2021
Q4 		$5.6M Buy
117,223
+17,211
+17% +$1.24M ﹤0.01% 3544
2021
Q3 		$9.27M Buy
100,012
+36,270
+57% +$4.72M ﹤0.01% 3285
2021
Q2 		$7.41M Buy
+63,742
New +$16.8M ﹤0.01% 3371

Other funds holding NRXP

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Vanguard Group's NRXP Position: Q4 2025 in Review

Vanguard Group increased its NRX Pharmaceuticals (NRXP) stake by 36% in Q4 2025, buying an estimated $523K and bringing the position to 729,842 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

Vanguard Group first reported a position in NRXP in Q2 2021 and has held it in 19 quarters since. The position peaked at $9.27M in Q3 2021. 28 funds tracked by Wall St. Rank hold NRXP as of Q4 2025.

  • Vanguard Group held 729,842 shares of NRX Pharmaceuticals worth $1.98M as of Q4 2025.
  • Vanguard Group bought 194,886 NRX Pharmaceuticals shares in Q4 2025, an estimated $523K.
  • NRX Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3564 holding.
  • Vanguard Group first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's NRX Pharmaceuticals position peaked at $9.27M in Q3 2021.
  • 28 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.